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Abstract
Introduction: Deregulation of the cell cycle machinery is often found in human cancers. Modulations in the cell
cycle regulator function and expression result not only in proliferative advantages, but also lead to tumor
progression and invasiveness of the cancer. In particular, cyclin D1 and p21 are often over-expressed in human
cancers, correlating with high tumor grade, poor prognosis and increased metastasis. This prompted us to
investigate the role of the cyclin D1/p21 signaling axis downstream of transforming growth factor beta (TGFb) in
breast cancer progression.
Methods: Cyclins mRNA and protein expressions were assessed by quantitative real-time PCR and Western blot in
triple negative breast cancer cell lines. Co-localization and interaction between cyclin D1 and p21 were performed
by immunocytochemistry and co-immunoprecipitation, respectively. Cell migration was assessed by wound healing
and quantitative time-lapse imaging assays. In addition, the effects of cyclin D1 on cellular structure and actin
organization were examined by staining with F-actin marker phalloidin and mesenchymal intermediate filament
vimentin. Finally, a mammary fat pad xenograft mouse model was used to assess mammary tumor growth and
local invasion.
Results: We found TGFb to specifically up-regulate the expression of cyclin D1 in triple negative breast cancer
cells. Induction of cyclin D1 is also required for TGFb-mediated cell migration. Suppression of cyclin D1 expression
not only resulted in a rounded and epithelial-like phenotype, but also prevented TGFb-induced vimentin and
F-actin co-localization at the cell edge as well as invadopodia formation. Furthermore, TGFb promoted the nuclear
co-localization and physical interaction between cyclin D1 and p21. The co-expression of cyclin D1 and p21
proteins are required for the initial steps of tumor development, as double knockdown of these two molecules
prevented primary tumor formation in a Xenograft mouse model. Moreover, the in vivo studies indicated that
locally advanced features of the invasive tumors, including skeletal muscle, mammary fat pad and lymphovascular
invasion, as well as ulcerated skin, were attenuated in the absence of cyclin D1 and p21.
Conclusions: Thus, our findings highlight the cyclin D1/p21 signaling axis as a critical regulator of TGFb-mediated
tumor growth initiation and local tumor cell invasion, both in vitro and in vivo.
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Introduction
Metastatic cancer is a largely incurable disease and
responsible for 90% of human cancer deaths [1]. To
develop metastasis in a distant organ, cancer cells must
initially disseminate from the primary tumor and invade
through the surrounding basement membrane and
stroma into lymphatic or blood vessels, followed by sur-
vival, extravasation and re-implantation at a secondary
site [2]. As cancer cell motility and invasiveness are cri-
tical features in the initial development of metastasis,
many molecules involved in these processes are becom-
ing attractive therapeutic targets [3]. Understanding the
molecular mechanisms that govern these early processes
may provide insightful strategies for the prevention of
cancer progression and metastasis.
The transforming growth factor beta (TGFb) superfam-
ily is comprised of many members, including activins,
anti-Müllerian hormone, bone morphogenetic proteins,
growth and differentiation factors, inhibins and TGFbs [4].
Among these family members, TGFb ligands and its
receptors are widely expressed in all tissues and the regu-
latory role played by these growth factors is of central
importance to human cancer development and progres-
sion. TGFb can be released from storage sites in the extra-
cellular matix (ECM) and bone, as well as secreted in a
paracrine and autocrine manner by platelet, myeloid,
mesenchymal and cancer cells [5-7]. The increasing
amount of TGFb1 is correlated with a high incidence of
distant metastasis as TGFb acts on the tumor cells and the
surrounding stroma to promote epithelial to mesenchymal
transition (EMT), ECM degradation, cell migration, cell
invasion, angiogenesis, immunosuppression and modifica-
tion of the tumor microenvironment [8-11]. Intravital ima-
ging of live tumor-bearing nude mice demonstrated that
active TGFb signaling is heterogeneously distributed in a
minority of cancer cells within primary mammary tumors
[12]. The activation of TGFb signaling promotes single
tumor cell migration and metastatic spread into blood ves-
sels and lymph nodes. However, not all cells with active
TGFb signaling are migratory, suggesting differential
TGFb signaling events and specific downstream targets
are required for this process.
TGFb signal transduction begins with ligand binding
to the TGFb type II receptor, which recruits and acti-
vates the type I receptor. The activated type I receptor
then phosphorylates intracellular mediators known as
receptor-regulated Smads (R-Smads), Smad2 and
Smad3. This phosphorylation event allows for subse-
quent heterotrimerization of two phosphorylated R-Smad
subunits with one common partner, Smad4 [13,14]. The
Smad heterotrimer then translocates to the nucleus
where it can bind DNA, but with a very low affinity [15].
In order to achieve high affinity binding, the Smads
associate with various DNA binding partners [16]. It is
thought that these partner proteins, which act as co-
activators or co-repressors, are functionally expressed in
different cell types, thus providing a basis for tissue and
cell type-specific functions for TGFb ligands [17].
Perturbations in the regulation of the cell cycle machin-
ery often occur in human cancers, resulting in an imbal-
ance between cell growth and cell death [18]. In addition,
several reports have proposed that deregulation of cell
cycle regulators results not only in proliferative advan-
tages, but also in increased tumor progression and aggres-
siveness traits [19]. Cell cycle progression is primarily
mediated through interactions between the different
cyclins with their respective cyclin-dependent kinases
(CDKs). Among the different cyclins, cyclin D1 and cyclin
E are associated with the G1-S phase transition [20].
Cyclin D1 interacts with CDK4 and 6, while cyclin E inter-
acts more specifically with CDK2 [21-25]. The activity of
the cyclin-CDK complexes is regulated by two classes of
small proteins referred to as cyclin-dependent kinases
inhibitors (CDKIs). The INK4 family, which includes
p15INK4, p16INK4A, p18INK4C and p19INK4D, specifi-
cally binds to CDK4 and 6, thereby preventing their asso-
ciation with the D-type cyclins [26-29]. The KIP family
includes p21CIP1/WAF1 (p21), p27KIP1 and p57KIP2
[30-35]. While the KIP family members are usually asso-
ciated with cyclin E-CDK and cyclin A-CDK complexes,
many reports indicated that they also interact with cyclin
D-CDK complexes [30,36-38].
Many of these cell cycle regulators are primary targets of
TGFb signaling in human cancers [39-41]. Interestingly,
some of these cell cycle regulators, in particular cyclin D1
and p21, are often over-expressed in many human cancers
and their levels are correlated with high tumor grade, poor
prognosis, and increased metastasis in subsets of carcino-
mas such as breast, prostate, cervical carcinomas and
lymphomas [42,43]. We previously demonstrated that p21
is a transcriptional co-regulator of Smad that mediates
TGFb-induced breast cancer cell migration and invasion in
metastatic breast cancer cells [44]. This prompted us to
explore the roles of other cell cycle regulators in promoting
tumor progression in breast cancer, aside from their well-
established functions in cell cycle regulation. Thus, we
investigated the effects of cyclins, in particular cyclin
D1, downstream of TGFb-mediated tumor progression.
Indeed, several studies have supported the notion that
the oncogenic effects of cyclin D1 may not be simply due
to enhanced tumor cell growth or proliferation. These
include reports showing a lack of correlation between cell
proliferation and cyclin D1 expression in several large
cohorts of 779 breast cancer patients [45,46] and the fact
that elevated cyclin D1 expression is associated with a high
incidence of metastasis and poor survival outcome [47,48],
suggesting that cyclin D1 may play a role in promoting
invasiveness of established tumors.
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In this study, we found that TGFb induced mRNA and
protein expression of cyclin D1 in breast cancer cells with
a highly migratory phenotype. Moreover, we found TGFb
to induce complex formation and nuclear co-localization
of cyclin D1 and p21, indicating that these two proteins
may cooperate to mediate TGFb functions in aggressive
human breast cancer cells. Furthermore, using gene silen-
cing approaches, our results indicate that TGFb-mediated
cyclin D1 expression is a prerequisite for TGFb-induced
breast cancer cell migration. Orthotopic injection of cyclin
D1/p21 null human breast cancer cells in nude mice con-
siderably reduced mammary tumor growth in vivo, com-
pared to animals injected with parental tumor cells.
Moreover, we found that following fat pad transplantation,
parental breast cancer cells invaded into the surrounding
mammary tissues, while these effects were blocked when
cyclin D1 and p21 gene expression were silenced. Collec-
tively, these data indicate that TGFb-mediated cyclin D1
and p21 gene expression leads to increased breast cancer
migration and invasion in vitro and that blocking expres-
sion of these two cell cycle regulators in aggressive human
breast tumors significantly reduced both tumor formation
and local tumor invasion into the surrounding tissues
in vivo.
Methods
Cell culture and transfection
Human breast cancer cell lines MDA-MB-231 (hereafter
referred to as MDA) and SCP2 (provided by Dr. Joan
Massagué) were cultured in DMEM containing 10%
fetal bovine serum (FBS) and 2 mM L-glutamine.
SUM149PT, SUM159PT and SUM229PE (provided by
Dr. Stephen P. Ethier) were plated in F-12 HAM’S nutri-
ent mixture (HyClone Laboratories, Inc., Logan, UT,
USA) containing 5% FBS, 5 μg/ml insulin (Sigma-
Aldrich, St. Louis, MO, USA), and 1 μg/ml hydrocorti-
sone (Sigma). SUM1315MO2 were cultured in F-12
HAM’S nutrient mixture (HyClone) containing 5% FBS,
5 μg/ml insulin (Sigma), and 10 ng/ml epidermal growth
factor (EGF) (Sigma). All cell lines were grown at 37°C
in 5% CO2. Before stimulation with 5 ng/ml TGFb1
(PeproTech, Rocky Hill, NJ, USA), cells were serum-
starved overnight. For cell transfection, flag-tagged p21
cDNA (Addgene plasmid 16240), HA-tagged cyclin D1
cDNA (Addgene plasmid 11181), scrambled and cyclin
D1 siRNAs (Sigma) were transfected using Lipofecta-
mine™ 2000 (Invitrogen, Carlsbad, CA, USA), according
to the manufacturers’ protocols.
Western blot analysis and immunoprecipitation
Protein extraction buffer containing 10 mM Tris-HCl, pH
7.5, 5 mM EDTA, 150 mM NaCl, 30 mM sodium pyro-
phosphate, 50 mM sodium fluoride, 1 mM sodium ortho-
vanadate, 1% Triton X-100 and protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin hydro-
chloride, 10 μg/ml aprotinin and 10 μg/ml pepstatin A)
were freshly prepared and kept at 4°C before cell lysis.
After cell lysates were centrifuged at 14,000 rpm for
15 minutes at 4°C, the concentration of total protein was
quantified using a BCA protein assay kit (Thermo Scienti-
fic, Rockford, IL, USA). Cell lysates were boiled with 6×
sodium dodecyl sulfate (SDS) Laemmli sample buffer for
five minutes and subjected to immunoblot using mouse
anti-p21 and rabbit anti-cyclin D1 antibodies (1:1,000 dilu-
tion, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
p21 and cyclin D1 were immunoprecipitated overnight at
4°C using their respective antibodies and followed by the
addition of protein G-Sepharose beads (GE Healthcare
Bio-Sciences, Piscataway, NJ, USA) for one hour at 4°C.
The immunocomplexes were washed four times with cold
lysis buffer and then subjected to Western blot.
Real-Time PCR
TRIzol reagent (Invitrogen) was used to extract total RNA
and reverse transcription of total RNA was carried out
using M-MLV reverse transcriptase and random primers
(Invitrogen) according to the manufacturer’s instructions.
SsoFast™EvaGreenÒ Supermix (Bio-Rad, Hercules, CA,
USA) was used for amplification of the cyclin D1 mRNA
in a Rotor Gene 6000 PCR detection system (MBI Lab
Equipment, Montreal Biotech Inc., Kirkland, QC, Canada).
The conditions for PCR were as follows: 95°C for 30 s, 40
cycles (95°C for 5 s and 59°C for 20 s). The primer
sequences were as follows: cyclin D1 forward primer,
AGCTGTGCATCTACACCGAC; reverse primer, ACTC-
CAGCAGGGCTTCGATCTG; GAPDH forward primer,
GCCTCAAGATCATCAGCAATGCCT; reverse primer,
TGTGGTCATGAGTCCTTCCACGAT.
Kinetic cell migration assay
Cell migration was performed as previously described [44].
Briefly, 50,000 cells per well were cultured in Essen Image-
Lock 96-well plates (Essen Bioscience, Ann Arbor, MI,
USA). The confluent cell layers were scratched to generate
a wound using the Essen Wound maker. Cells were then
treated in the presence or the absence of 5 ng/ml of
TGFb1. The images/videos of the wound were automati-
cally taken at the exact same location using the IncuCy-
te™software (Essen Bioscience). Wound width, wound
confluence or relative wound density were automatically
measured by the IncuCyte software.
Transwell cell migration assay
Transfected cell suspensions (40,000 cells/well) were
seeded in 24-well Cell Culture Inserts (8-μm pore size;
BD Biosciences, Mississauga, ON, Canada). After 24
hours incubation, the cells that migrated to the bottom
of the membrane were fixed with 3.7% formaldehyde for
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10 minutes and then labeled with the near-infrared
fluorescence DNA binding dye DRAQ5 (2 μg/ml in
PBS) at 37ºC for 5 minutes. The fluorescence intensity
of migrated cells was measured at 700 nm in a near-
infrared fluorescence imager (Odyssey CLX, LI-COR
Biosciences - Biotechnology, Lincoln, NE, USA) using
the Image Studio software (LI-COR Biosciences -
Biotechnology).
Immunofluorescence microscopy
For the invadopodia formation assay, cells were grown
on top of eight-well chamber slides coated with 100 μl
growth factor-reduced Matrigel. After TGFb treatment
for 24 hours, cells were fixed with 3.7% formaldehyde
for 10 minutes, permeabilized in 0.1% Triton X-100 for
3 minutes, and blocked for 1 hour in 2% bovine serum
albumin (BSA). Fixed cells were incubated with primary
antibodies against p21, cyclin D1, F-actin and vimentin
for one hour and followed by the secondary antibodies
Alexa Fluor®568 goat anti-rabbit IgG and Alexa
Fluor®488 goat anti-rabbit (1:800 dilution; Invitrogen) for
one hour. Nuclei were stained with DAPI (Invitrogen).
Confocal analysis was performed using a Zeiss LSM 510
Meta Axiovert confocal microscope (Carl Zeiss, Oberko-
chen, Baden-Württemberg, Germany) using the 63×
objective.
Mammary fat pad injection of nude mice
The animal study and SCP2 cells used in the mice model
were approved by the McGill ethics committee (University
Animal Care Committee, UACC) and all the experimental
animal protocols were in accordance with the McGill Uni-
versity Animal Care. Four- to six-week old female Balb/c
nude mice (Charles River Laboratories International,
Wilmington, MA, USA) were used as a model for asses-
sing mammary tumor formation and local invasion.
An anesthetic cocktail of ketamine (50 mg/kg), xylazine
(5 mg/kg) and acepromazine (1 mg/kg) was injected intra-
muscularly into mice (six per group). Fifty thousand par-
ental SCP2 cells or p21 and cyclin D1 double knockdown
SCP2 cells in 100 μl of saline (20% Matrigel) were injected
into the mice mammary fat pads using a 30-gauge needle.
Tumor growth and size were measured using a caliper. At
eight weeks post-injection, mice were sacrificed and mam-
mary tumors with surrounding skin and tissues were fixed
in 10% neutral-buffered formalin for one day. Sections of
mammary tumor were embedded in Tissue-Tek O.C.T.
(VWR International, Radnor, PA, USA) compound and
9 μm thick sections were stained with hematoxylin and
eosin to assess local advanced features, including skeletal
muscle, mammary fat pad, and lymphovascular invasion as
well as skin ulceration. Images of the tumors were photo-
graphed by light microscope using 10× and 20× objectives.
For intratibia injections, parental and p21/cyclin D1-
depleted SCP2 cells (2.0× 106) were injected intramus-
cularly into the left tibia of two group mice (six per
group). The mice were monitored weekly for tumor bur-
den. Digital radiography of hind limbs of all animals was
used to monitor the development of skeletal lesions at
four, six and eight weeks post-injection in a MX-20
cabinet X-ray system (Faxitron X-ray Corp.). On week
8, radiographs of anesthetized mice were taken.
Statistical analyses
The difference between groups was analyzed using Stu-
dent’s t-test, and *P <0.05 was considered statistically
significant.
Results
TGFb induces cyclin D1 expression in highly migratory
breast cancer cells
We have previously shown that TGFb’s pro-migratory and
invasive effects are mediated through the induction of p21
in highly migratory triple negative breast cancer cells [44].
Due to the fact that p21 is a universal regulator of cyclin/
CDKs, this prompted us to investigate whether additional
cell cycle regulators downstream of TGFb are involved in
this process. Moreover, because multiple studies have sug-
gested that the oncogenic effects of cyclins may not be
simply due to enhanced tumor cell growth or proliferation
but may also involve tumor promoting functions [45-48],
we examined the effect of TGFb on protein expression
levels of cyclins A, B1, D1 and D2 in the human aggressive
breast cancer cell lines MDA and its metastatic sub-
progeny SCP2 [49]. As shown in Figure 1A, we found that
TGFb significantly increased cyclin D1 protein expression
in a time-dependent fashion. The effect of TGFb on cyclin
D1 expression was specific, as protein levels of G1 and S
phase regulators cyclin D2 and A remained unchanged in
response to TGFb stimulation. The M phase cyclin B1 was
barely detectable. As a positive control, we measured the
expression of p21, which we have previously shown to be
potently induced by TGFb in MDA cells [44]. TGFb
induced the expression of p21 in a similar temporal
expression pattern as cyclin D1 in these breast cancer
cells. To assess whether TGFb regulates cyclin D1 at the
transcriptional level, we measured mRNA levels of cyclin
D1 by quantitative PCR in SCP2 cells stimulated with
TGFb for 2, 6 and 24 hours. Induction of cyclin D1
mRNA by TGFb was already detectable at 2 hours and
was sustained for up to 24 hours (Figure 1B). These results
highlight cyclin D1 as a novel TGFb downstream target
gene in human breast cancer cells.
To determine whether there was an association between
TGFb induction of cyclin D1 and TGFb’s pro-migratory
effect, we measured the mRNA level of cyclin D1 in a
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panel of triple negative breast cancer cell lines which are
either insensitive (SUM1315) or responsive (SUM149 and
SUM159) to TGFb-mediated cell migration and invasion
[44]. Interestingly, TGFb potently and persistently up-regu-
lated cyclin D1 mRNA in the highly migratory cell lines
SUM149 and SUM159, but not in the TGFb-insensitive
SUM1315 cell line (Figure 1C). Together, these results
indicate that TGFb-induced cyclin D1 expression corre-
lates with TGFb-induced p21 gene expression and cell
migration, thus, suggesting that cyclin D1 may be asso-
ciated with p21 and participate in TGFb tumor-promoting
functions in breast cancer cells.
TGFb promotes cyclin D1 nuclear accumulation and
co-localization with p21
The intracellular localization of cyclin D1 is important
for its function and is, therefore, tightly regulated [50].
Constitutive accumulation of cyclin D1 in the nucleus
has been shown to promote tumor transformation [51].
To determine whether TGFb regulates cyclin D1 nuclear
localization, we assessed the localization of cyclin D1 in
MDA and SCP2 cells treated with or without TGFb for
24 hours by confocal immunofluorescence microscopy.
Cyclin D1 was predominantly found in the cytosol in
unstimulated cells, whereas it appeared to be primarily
retained within the nucleus after treatment with TGFb
(Figure 2A).
We have previously shown that TGFb induces protein
expression and nuclear localization of p21 in triple nega-
tive breast cancer cells [44]. The concurrent TGFb effect
on p21 and cyclin D1 prompted us to determine whether
these molecules co-localize within the nucleus in response
to TGFb. As shown in Figure 2B, TGFb facilitates nuclear
co-localization of cyclin D1 and p21 in MDA cells. The
simultaneous induction and co-localization in the nucleus
of cyclin D1 and p21 by TGFb suggested that they may be
physically associated with each other. To address this, we
performed co-immunoprecipitation of p21 and cyclin D1
in MDA and SCP2 cells treated with or without TGFb for
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Figure 1 TGFb induces cyclin D1 expression in highly migratory breast cancer cells. (A) MDA and SCP2 cells were stimulated with or
without 5 ng/ml transforming growth factor beta (TGFb) for the indicated times. Total cell lysates were subjected to immunoblot using cyclin
D1, cyclin D2, cyclin A, cyclin B1, p21, p-Smad2, p-Smad3 and b-tubulin antibodies. Densitometry analysis of cyclin D1 protein expression was
performed on four separate independent experiments (right panel). (B and C) cyclin D1 mRNA levels were measured by real-time PCR (error
bars indicate SEM; n = 3 independent experiments) for the indicated cell lines.
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Figure 2 TGFb promotes cyclin D1 nuclear accumulation and co-localization with p21. (A) MDA and SCP2 cells were treated with or
without 5 ng/ml transforming growth factor beta (TGFb) for 24 hours. Immunocytochemistry was performed using cyclin D1 (red) antibody and
DAPI (blue). The scale bar is 10 μm. (B) MDA cells were immunostained using p21 (green) and cyclin D1 (red) antibodies. Co-localizaton (yellow)
between p21 and cyclin D1 is represented by overlay. (C) MDA and SCP2 cells were treated with TGFb for the indicated times. Cell lysates were
analyzed by co-immunoprecipitation using an anti-cyclin D1 antibody. Immunoprecipitated cyclin D1 was subjected to Western blotting.
(D) MDA, SUM149 and SUM159 cells were treated with TGFb. Cell lysates were immunoprecipitated using an anti-p21 antibody and analyzed by
immunoblotting using anti-cyclin D1 and anti-p21 antibodies.
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the interaction between endogenous p21 with cyclin D1 in
a time-dependent fashion in MDA and SCP2 cells.
Reciprocal immunoprecipitation experiments confirmed
that endogenous cyclin D1 specifically interacts with
immunoprecipitated p21 in response to TGFb in MDA
cells (Figure 2D, left panel). Moreover, the induction of
complex formation between endogenous cyclin D1 and
p21 was also observed in both SUM149 and SUM159 cells
(Figure 2D, middle and right panels). Collectively, these
results indicated that TGFb stimulates the formation of a
complex between cyclin D1 and p21 in triple negative
basal-like breast cancer cells.
Cyclin D1 is required for TGFb-mediated cell migration
Given that TGFb enhanced cyclin D1 and p21 expression
and complex formation in these human metastatic breast
cancer cells, we investigated whether the TGFb pro-
migratory effect is mediated through cyclin D1. To
address this, SCP2 cells were transfected with scrambled
(Scr) siRNA or cyclin D1 siRNA. Cell migration in
response to TGFb was assessed by the scratch/wound
healing assay coupled to quantitative time-lapsed imaging
for up to 24 hours. As shown in Figure 3A, TGFb-
induced cyclin D1 protein expression in the SCP2 cells
transfected with Scr siRNA was blocked in cells trans-
fected with cyclin D1 siRNA. As shown in Figure 3B, C,
while TGFb stimulated rapid wound closure in SCP2
cells transfected with the Scr siRNA, this effect was
delayed in SCP2 cells depleted of cyclin D1. TGFb-
induced wound closure was not affected by the mitotic
inhibitor mitomycin C, suggesting that the effect of
TGFb on cell migration was independent of cell prolifera-
tion (Figure 3D). We further assessed the role of cyclin
D1 downstream of TGFb-mediated cell migration, using
a Transwell migration assay. As shown in Figure 3E, F,
knocking down cyclin D1 inhibited the TGFb pro-
migratory effects, consistent with what observed with the
wound healing assay (Figure 3B, C).
To then address whether cyclin D1 and p21 have any
synergistic effect, p21 and cyclin D1 cDNAs were over-
expressed alone or in combination and the TGFb effect
on cell migration was examined using both the wound
healing and Transwell migration assays. As shown in
Figure 3G, overexpression of cyclin D1 or p21 alone had
little or no potentiation effect on TGFb-induced cell
migration. However, overexpression of both proteins
clearly increased/potentiated the TGFb effect, suggesting
that these two proteins synergize their effect downstream
of TGFb. This is consistent with our main finding and
conclusion, showing that the two proteins cooperate to
regulate TGFb-mediated breast cancer cell migration and
tumor local invasion. Together, these results demonstrate
that cyclin D1 is required for TGFb-mediated migration
in breast cancer cells.
Cyclin D1 is a downstream mediator in TGFb-regulated
actin reorganization and invadopodia formation
Cyclin D1 has previously been reported to regulate cellu-
lar migration in primary bone macrophages, mouse
embryo fibroblasts (MEFs), and breast cancer cells
[52-54]. For instance, cyclin D1-deficient MEFs display a
more spread phenotype, and an increased cell adhesion
and actin stress fiber formation through inhibition of
thrombospondin 1 and ROCK signaling [53]. Therefore,
we examined whether cyclin D1 effects on cellular struc-
ture and actin organization contribute to TGFb-mediated
cancer cell migration. To this end, SCP2 cells transfected
with either Scr or cyclin D1 siRNAs were stimulated with
TGFb and the dynamics of actin organization were
assessed by staining with the fluorescently labeled F-actin
marker phalloidin and mesenchymal intermediate fila-
ment vimentin. As shown in Figure 4A, vimentin fila-
ments co-localized with F-actin at the leading edge of
aggressive SCP2 cells transfected with Scr siRNA, which
displayed an elongated phenotype in response to TGFb.
Interestingly, cyclin D1-deficient cells were rounded and
exhibited more epithelial-like phenotype. Furthermore,
suppression of cyclin D1 expression not only prevented
the elongation of vimentin filaments, but also the co-
localization with F-actin at the cell edge.
Vimentin is required for the elongation of invadopodia
subcellular structures, which are three-dimensional
actin-rich protrusions [55]. Invadopodia are selectively
found in invasive cancer cells and are important for the
degradation of the ECM [56]. As cyclin D1 affects vimen-
tin distribution, we investigated whether cyclin D1 could
regulate invadopodia formation. SCP2 cells transfected
with either Scr or cyclin D1 siRNAs were seeded on top
of growth factor-reduced Matrigel and treated with or
without TGFb. Whereas Scr-transfected SCP2 cells sti-
mulated with TGFb showed increased F-actin-bundled
protrusion and invaded into the Matrigel, this phenotype
was completely abolished by knocking down cyclin D1
expression (Figure 4B). All together, these results defined
novel functions for cyclin D1 as a TGFb downstream tar-
get that is required for this growth factor to mediate
vimentin elongation, induction of a migratory morpholo-
gical phenotype, and the formation of invasive subcellular
structures in metastatic breast cancer cells.
Depletion of cyclin D1 and p21 prevents mammary tumor
growth and local invasion
Overexpression of p21 and cyclin D1 is correlated with
poor prognosis and aggressiveness in breast cancer. To
address the importance of p21 and cyclin D1 on breast
cancer development in vivo, we injected either SCP2 con-
trol or double p21 and cyclin D1 knockdown cells into
the mammary fat pads of female Balb/c nude mice to
monitor primary tumor growth and local invasiveness.
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Figure 3 Cyclin D1 is required for TGFb-mediated cell migration. (A) SCP2 cells were transfected with Scr or cyclin D1 siRNAs and then
treated with or without 5 ng/ml transforming growth factor beta(TGFb) for 24 hours. Total cell lysates were analyzed for cyclin D1 and b-tubulin
by Western blotting. (B) Representative images of phase contrast and wound mask of transfected SCP2 cells stimulated without or with TGFb for
0 and 24 hours in scratch/wound healing assay. The initial wound mask (black) and wound closure (grey) were measured using the Essen
Instruments Scratch Wound Module. (C) Relative wound width was analyzed by the IncuCyte™software (Essen Bioscience) and quantified for the
indicated times (error bars indicate SEM; n = 3 independent experiments). (D) SCP2 cells were treated with either vehicle (dimethyl sulfoxide,
DMSO) or mitomycin C (Mito C) in the presence or absence of TGFb. SCP2 cell migration was quantified using wound closure area at 24 hours
(error bars indicate SEM; n = 3 independent experiments). (E) Representative images of transfected SCP2 cells stimulated with or without TGFb
for 0 and 24 hours in Transwell cell migration assay. Cells were stained with 0.2% crystal violet. (F) Transfected and migrated SCP2 cells in
Transwell migration assay were stained with DRAQ5 fluorescent dye and quantified using fluorescent density at 24 hours (error bars indicate
SEM; n = 3 independent experiments). (G) SCP2 cells were transfected with empty vector, Flag-p21, and HA-cyclin D1 separately or in
combination. TGFb-mediated cell migration was assessed using the Transwell (top panel) and wound healing (bottom panel) assays. Migration of
the cells was quantified using fluorescent density (Transwell assay) and wound closure area (wound healing assay) at 24 hours (Error bars
indicate SEM; n = 3 independent experiments).
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Figure 4 Cyclin D1 is a downstream mediator in TGFb-regulated actin reorganization and invadopodia formation. (A) Scr siRNA- or
cyclin D1 siRNA-transfected SCP2 cells were treated with or without 5 ng/ml transforming growth factor beta (TGFb) for 24 hours.
Immunocytochemistry was performed using F-actin (green) antibody, vimentin (red) antibody and DAPI (blue). Co-localizaton (yellow) between
F-actin and vimentin is represented by overlay. The scale bar is 10 μm. (B) Scr siRNA- or cyclin D1 siRNA-transfected SCP2 cells were cultured on
the top of growth factor-reduced Matrigel and then treated with or without 5 ng/ml TGFb for 24 hours. Immunocytochemistry was performed
using F-actin (green) and cyclin D1 (red) antibodies and DAPI (blue).
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Silencing p21 and cyclin D1 expression using siRNAs sig-
nificantly reduced the rate of primary tumor formation
and tumor size (Figure 5A). As depletion of p21 alone
did not affect tumor formation in a Xenograft transplan-
tation in vivo model [55], it is likely that the observed
phenotype on tumor formation in the double knockdown
is mediated by cyclin D1. This is in agreement with
previous studies showing that depletion of cyclin D1 pre-
vented tumor development in oncogenic HER2 overex-
pressing transgenic mice [57-59]. Importantly, three out
of six mice in the control group had tumors ulcerating
through the overlaying skin, while all the mice in the
double knockdown group had intact skin. Breast tumor
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Figure 5 Depletion of cyclin D1 and p21 prevents mammary tumor growth and local invasion. (A) Parental SCP2 and p21/cyclin D1
double knockdown SCP2 cells were implanted into the mammary fat pad of four- to six-week-old female Balb/c nude mice. Mammary tumor
growth was measured from two sets of mice and quantified for the tumor size at the indicated times (six per group; error bars indicate SEM).
(B) Representative photographs show hematoxylin and eosin staining of the mammary gland (tumor and surrounding tissues) of mice at eight
weeks post-injection. (C) Representative photographs show PTGS2 staining of parental and p21/cyclin D1-depleted mammary tumor of mice at
eight weeks post-injection. (D) Representative radiographs of skeletal lesions in two groups of mice (parental and p21/cyclin D1-depleted SCP2)
were taken by X-ray using Faxitron. Parental and p21/cyclin D1-depleted SCP2 cells were injected in tibia. The lesions are highlighted by arrows.
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advanced breast cancer. All tumors were taken with the
overlaying skin and surrounding tissues and subjected to
hematoxylin and eosin staining. As shown in Figure 5B,
the deep tumor margins in the control group were less
distinct, invading nearby structures, including skeletal
muscles and the mammary fat pad, and showed frequent
lymphovascular invasion. However, the tumor margins in
the knockdown group were well encapsulated with a
non-invasive nature. In addition, we performed immuno-
histochemistry on primary mammary tumor derived
from animals injected with parental and p21/cyclin D1-
depleted SCP2 cells. We assessed the expression of the
TGFb-regulated gene PTGS2, which we have previously
shown to be involved in mediating the TGFb effect on
cell migration and invasion [44]. As shown in Figure 5C,
using tumors from four different mice in each group, we
found expression of PTGS2 to be clearly higher in paren-
tal tumors compared to p21/cyclin D1-depleted tumors,
further confirming that the p21/cyclin D1-depleted
tumors displayed less invasive features.
To investigate the role of p21 and cyclin D1 on the
development of bone osteolytic lesions, parental and dou-
ble knockdown SCP2 cells were injected intramuscularly
into the left tibia of two groups of nude mice. As shown in
Figure 5D, following X-ray examination of the bones, both
group of mice developed secondary tumors that caused
severe osteolytic bone lesions, suggesting that p21/cyclin
D1 do not affect the later stages of bone metastasis. Col-
lectively, these results indicate that while p21 and cyclin
D1 are required for breast cancer cells to acquire an inva-
sive phenotype, their effects are primarily occurring at the
earlier stages of tumor metastasis, namely induction of
local cell invasion from the tumor to the surrounding tis-
sues. This is also consistent with previous work, showing
that depletion of p21 alone did not affect the development
of bone osteolytic lesions [44].
Discussion
Cyclin D1 is a well-characterized oncogene that is fre-
quently overexpressed in human breast, lung, colon, pros-
tate and hematopoietic carcinomas [60-62]. This is a
unique feature among the three closely related D type G1
cyclins (D1, D2 and D3), as amplification of cyclin D2 and
D3 copy-number is rarely observed in human cancer. In
fact, methylation of cyclin D2 resulting in loss of its
expression has been reported in breast, pancreatic and
prostate cancer [63-65]. In addition to the association
between cyclin D1 expression and human cancer, overex-
pression of cyclin D1 is tumorigenic, as supported by evi-
dence that MMTV-driven cyclin D1 is sufficient for
mammary hyperplasia and carcinoma development in
transgenic mice [66]. Furthermore, cyclin D1 is required
for many oncogenes, such as HER2 or Ras, to induce
mammary tumor growth in mice [57-59]. The function of
cyclin D1 in mammary oncogenesis in mice is mediated
through the activation of its regulatory partner CDK4, as
mice lacking CDK4 or expressing the CDK4/CDK6-speci-
fic inhibitor INK4A are resistant to HER2-induced mam-
mary tumor formation [58,67-69]. While these studies
addressed the importance of cyclin D1 on breast tumor
initiation, its contribution to the development and pro-
gression of established tumors remains unclear.
Several studies support the notion that the oncogenic
effects of cyclin D1 may not be simply due to enhanced
tumor cell growth or proliferation. For instance, cyclin D1
expression did not correlate with Ki67 expression in a
cohort of 779 breast cancer patients [45]. In another study
of 1,740 breast cancer patients, cyclin D1 expression was
not tightly associated with proliferative genes that are
regulated by the inactivation of CDK4 substrate RB [46].
In addition, high expression of cyclin D1 is associated with
high incidence of metastasis and poor survival outcome
[47,48]. Therefore, cyclin D1 is potentially required for
continual development and progression of established
tumors.
In this study, we investigated the function of cyclin D1
on breast tumor progression induced by TGFb, a potent
tumor-promoting factor, in metastatic breast cancer cell
lines. Our results showed that the effect of TGFb on cyclin
D1 expression was specific, as protein levels of other
cyclins in G1, S and M phase are unresponsive to TGFb
stimulation. Furthermore, using a panel of tumorigenic tri-
ple negative breast cancer cell lines, which exhibit differen-
tial responses to TGFb in terms of cellular migration, we
found cyclin D1 expression to correlate with p21 expres-
sion and to be required for TGFb-induced cell migration.
Furthermore, up-regulation of the cyclin D1 gene by
TGFb is more potent and persistent in highly migratory
cell lines compared with less motile cells. This is consis-
tent with a previous study using intravital imaging of live
tumor-bearing nude mice, showing that although TGFb
signaling promotes single tumor cell migration and meta-
static spread into blood vessels and lymph nodes, not all
cells with active TGFb signaling are migratory [12]. Our
results suggest that cyclin D1 is a specific downstream tar-
get for TGFb-mediated cell migration.
Subcellular localization and stabilization of cyclin D1
play an important role in human cancers [70]. We showed
a TGFb-induced nuclear localization of cyclin D1 in these
metastatic breast cancer cell lines. It has been demon-
strated that oncogenic actions of cyclin D1 are predomi-
nantly nuclear in many cancers, as carcinogenic mutations
and deletions often occur at the T286 site, which controls
cyclin D1 protein turnover and nuclear export [71,72].
Mutated cyclin D1 with constitutive nuclear localization
and impaired degradation not only enhanced cyclin D1
transformation efficiency in vitro, but also promoted
tumor formation in vivo [73]. Our study further revealed
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that TGFb-induced nuclear cyclin D1 promotes cell
migration by altering cell morphology and the formation
of invasive subcellular structures in metastatic breast can-
cer cells.
Cyclin D1 has been recognized as a multifunctional pro-
tein, which regulates angiogenesis, lipogenesis, mitochon-
drial function and cell migration [53,54,74-78]. A recent
study identified that more than 100 cyclin D1-interacting
proteins are involved in the regulation of cell cycle, tran-
scription, DNA repair, RNA metabolism, protein folding
and cell structure [79], suggesting that these interactors
might influence various biological functions of cyclin D1.
It has been shown that p21 interacts with cyclin D1 to
promote nuclear accumulation of cyclin D1 [80]. In addi-
tion, cyclin D1 associates with p21 to facilitate DNA
repair, and this function of cyclin D1 is independent of
CDK4 activation [81,82]. We demonstrated that in the
context of TGFb signaling, cyclin D1 associates with p21
in metastatic breast cancer cells. Furthermore, depletion of
cyclin D1 and p21 prevented mammary tumor formation
and subsequent local invasion into surrounding tissues.
Our previous study showed that p21 is required for
TGFb-mediated cell migration and invasion; therefore,
these results not only highlight cyclin D1 as a novel TGFb
downstream target, but also indicate that cyclin D1 coop-
erates with p21 to mediate the effect of TGFb on breast
cancer progression.
Conclusions
In this study, we showed that TGFb significantly induced
cyclin D1 expression in metastatic breast cancer cells.
TGFb-induced cyclin D1 and p21 proteins remain mostly
co-localized in the nucleus and physically interact with
each other. Importantly, we found that up-regulated p21
and cyclin D1 play an important role in TGFb regulation
of cellular migration and invasion by actin remodeling.
These results suggest that cyclin D1 and p21 may coop-
erate with each other to mediate the tumor-promoting
effects of TGFb in aggressive breast cancer cells.
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